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AbstrACt
Objectives We sought to understand why randomised 
controlled trials in septic shock have failed to demonstrate 
effectiveness in the face of improving overall outcomes for 
patients and seemingly promising results of early phase 
trials of interventions.
Design We performed a retrospective analysis of large 
critical care trials of severe sepsis and septic shock. 
Data were collected from the primary trial manuscripts, 
prepublished statistical plans or by direct communication 
with corresponding authors.
setting Critical care randomised control trials in severe 
sepsis and septic shock.
Participants 14 619 patients randomised in 13 trials 
published between 2005 and 2015, enrolling greater 
than 500 patients and powered to a primary outcome of 
mortality.
Intervention Multiple interventions including 
the evaluation of treatment strategies and novel 
therapeutics.
Primary and secondary outcome measures Our 
primary outcome measure was the difference between 
the anticipated and actual control arm mortality. 
Secondary analysis examined the actual effect size and 
the anticipated effect size employed in sample size 
calculation.
results In this post hoc analysis of 13 trials with 14 619 
patients randomised, we highlight a global tendency to 
overestimate control arm mortality in estimating sample 
size (absolute difference 9.8%, 95% CI −14.7% to −5.0%, 
p<0.001). When we compared anticipated and actual 
effect size of a treatment, there was also a substantial 
overestimation in proposed values (absolute difference 
7.4%, 95% CI −9.0% to −5.8%, p<0.0001).
Conclusions An interpretation of our results is that trials 
are consistently underpowered in the planning phase by 
employing erroneous variables to calculate a satisfactory 
sample size. Our analysis cannot establish if, given a 
larger sample size, a trial would have had a positive result. 
It is disappointing so many promising phase II results 
have not translated into durable phase III outcomes. It is 
possible that our current framework has biased us towards 
discounting potentially life-saving treatments.
IntrODuCtIOn  
The mortality from severe sepsis and septic 
shock has fallen demonstrably over the last 
few years.1 Despite this, many large interven-
tional trials in critical care, encompassing both 
novel therapeutics and optimised treatment 
strategies, have failed to confirm improved 
effectiveness of interventions in comparison 
with placebo or best routine care. Occasion-
ally, the promise hinted at by small phase 
II efficacy trials has not been confirmed in 
larger phase III effectiveness trials.
During the planning of an interventional 
trial, investigators must determine both the 
population and the number of subjects to be 
enrolled. This is to ensure that the sample size 
is adequate to identify with reasonable statis-
tical certainty both true differences and true 
lack of differences between groups, that is, 
avoiding both false-positive and false-negative 
results. To calculate the sample size, investi-
gators identify a significance level (commonly 
0.05) and a ‘power’ (commonly 80% to 90%). 
The significance level, often referred to as the 
alpha, is the chance of concluding there is 
evidence of a difference when actually there 
is not and the difference found in the trial was 
strengths and limitations of this study
 ► This study captures large contemporary trials in se-
vere sepsis and septic shock powered to mortality.
 ► Includes critical care trials independent of interven-
tion employed.
 ► Examines evidence from sources outside of pub-
lished trial manuscripts.
 ► Applies statistical analysis to the discrepancy be-
tween anticipated and actual variable used in trial 
design.
 ► The retrospective examination of effect size is limit-
ed by the proposed errors in sample size calculation.
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due to chance. Crudely, the power is the capacity of the 
trial to avoid erroneously reporting no difference when 
in fact there is a true difference between treatments. The 
input factors required to calculate the required sample 
size in a trial powered to a dichotomous outcome such as 
mortality are:
1. The control arm event rate.
2. The effect size.
3. The alpha level—to control for type 1 error (false pos-
itive).
4. And the power—to control for type 2 error (false 
negative).
Control arm event rates are commonly derived from 
prior trials, historical epidemiological studies or incep-
tion studies. Investigators draw inferences on outcome 
event rate from a population akin to their prospective 
study population (by employing similar inclusion and 
exclusion criteria). The effect size is defined as the differ-
ence in primary outcome rate between the control and 
intervention arms of a trial. Anticipated effect sizes are 
typically estimated from earlier phase ‘efficacy trials’; 
these data provide a prediction of the magnitude of an 
intervention in the trial population to be enrolled.
Given the appreciable numbers of recent trials that have 
not demonstrated statistically significant effectiveness, we 
speculated that the assumptions which investigators were 
making in planning their trials may have inadvertently 
designed in weaknesses such that the final result of the 
trial did not necessarily reflect the veracity or otherwise of 
the hypothesis being tested. To put this another way, we 
speculated that the assumptions used in determining trial 
design were erroneous and have systematically eroded 
the capacity of such trials to demonstrate either a true 
positive effect of the treatment being investigated or to 
confidently exclude any such treatment effect.
Thus, we sought to investigate the role of these two 
important estimated variables on the relative risk reduc-
tion in primary outcome measure. To do this, we exam-
ined first the difference between anticipated outcome 
control arm event rate used during trial planning and 
the actual control arm event rate in the trial report, and 
second the difference between the anticipated effect size 
of novel treatment and that subsequently reported in the 
trial publications.
MethODOlOgy
This study was performed as a post hoc analysis of 
published results of clinical trials in severe sepsis and 
septic shock.
A MEDLINE search was performed in August 2016 to 
identify appropriate trials by using the medical subject 
heading (MeSH) terms ‘sepsis’, ‘septic shock’ and 
‘randomised control trial’ with publication dates limited 
to 2005 to 2015. The publication list was independently 
accessed by two investigators (JLCW and SJB) and trials 
filtered against an a priori defined list of inclusion criteria 
(figure 1).
Those trials not matching all inclusion criteria were 
rejected. The two lists were then cross-checked to ensure 
uniformity. The list was subsequently passed on to a third 
sepsis expert investigator (ACG) to ensure the sample 
set was representative of the prevailing peer-reviewed 
literature. Two further trials were suggested at this point 
but were subsequently rejected, as the sample sizes were 
too small to be included in the analysis. The minimum 
number of enrolled subjects in trials was set at 500 for 
trials to be included in the analysis. This was somewhat 
arbitrary, but was chosen so that large efficacy studies were 
not included in the analysis; our objective was to explore 
the impact of our variables of interest in effectiveness 
trials with a clinical outcome measure—mortality. The 
statistical analysis plans from the papers identified were 
systematically analysed to collect information around trial 
power, anticipated control arm mortality and anticipated 
effect size. Sources of additional information included the 
examination of pretrial published protocols or statistical 
analysis plans or where necessary direct contact with the 
corresponding authors of the primary or protocol publi-
cations. The latter was undertaken if there were concerns 
that there could be potential ambiguity from our own 
interpretation of the published reports. These data were 
collated using Microsoft Excel (Microsoft, Seattle, Wash-
ington, USA), with statistical analysis performed using 
GraphPad Prism V.6 (GraphPad Software, La Jolla, Cali-
fornia USA) and R V.3.3.1.2
Data were initially checked for normality using the 
D’Augestino-Pearson Omnibus test and subsequently 
analysed using t-tests or non-parametric equivalents 
where appropriate.
Measures of uncertainty, specifically CIs for the actual 
control arm mortality, intervention arm mortality and 
effect size, were calculated in R from the data provided 
in the trial reports using standard formulae.3 The differ-
ences between the actual and anticipated control arm 
mortality have been summarised using a random-effects 
meta-analysis to allow for heterogeneity between studies. 
The power curve (figure 5) was created in R using the 
standard power calculation formula for comparing two 
proportions.4
Patient and public involvement
Patients and public were not involved in the creation of 
this manuscript as it examines previously published study 
data.
results
trials included in the final analysis
An initial MEDLINE search identified 251 articles 
matching the initial search criteria. Of these, 236 trials 
were excluded, as they did not meet the prespecified 
inclusion criteria; this resulted in 16 trials (figure 1).
Three trials were subsequently removed from the final 
analysis despite meeting the initial inclusion criteria. 
These were VISEP,5 APROCCHS6 and ART123.7 VISEP 
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and APROCCHS were excluded as one trial was stopped 
early for safety reasons and in the other the investigational 
drug (drotrecogin alpha (activated)) was withdrawn 
during the period of the trial. The resulting publications 
from these two studies did not provide the necessary data 
for us to use to explore our research questions. ART123 
was a phase IIb trial, which has now been restarted as a 
phase III trial ( ClinicalTrials. gov NCT01598831); we were 
unable to acquire sufficient data to explore our research 
questions from the original publication or following 
correspondence with the primary author. The 13 trials 
included in the final analysis are summarised in table 1. 
They form the basis for our exploration of control arm 
mortality and effect size estimate.
The primary end point of mortality was assessed at 
day 28 in seven trials, day 60 in one trial, day 90 in four 
trials and as in-hospital mortality in one trial. Sample 
size projections stated in statistical methods correlated 
well with the numbers of patients analysed in the final 
published intention-to-treat analysis groups. In ProCESS,8 
the sample size was recalculated after the first interim 
analysis, reducing the required sample size from 1950 
to a total of 1341 patients at the end of enrolment. This 
recalculation preserved power at the same absolute effect 
Figure 1 Trial selection screening and selection.  
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size, and the investigators adjusted their analysis plan for 
the expenditure of power due to an interim analysis. The 
ALBIOS9 trial size increased from an initial sample size 
of 1350 patients to a total of 1818 patients. This occurred 
after the second interim analysis by the Data Safety and 
Monitoring Board according to an a priori agreement with 
the investigators (L Gattinoni personal communication).
Anticipated control arm mortality and effect size
While all of the trials included patients with severe sepsis 
and septic shock, there remained considerable hetero-
geneity in detailed entry criteria. The trials and key 
characteristics are summarised in table 1. Figures 2 and 
3 demonstrate the difference in anticipated and actual 
control arm mortality rate for the trials included in our 
study. Overall, there was a tendency to substantially 
overestimate the control arm mortality, with strong 
evidence that the actual control arm mortality is lower than 
the anticipated control arm mortality (absolute differ-
ence, 9.8 percentage points; 95% CI −14.7% to −5.0%; 
p<0.001). In addition, there was a tendency to overesti-
mate the treatment effect with very strong evidence that 
the actual effect size is smaller than the anticipated effect 
size (absolute difference, 7.4 percentage points; 95% CI 
−9.0% to −5.8%; p<0.0001), summarised in figure 4.
Taken overall, in these trials there has been a tendency 
to overestimate the anticipated rate of the primary 
outcome and overestimate the effect size of the treat-
ment being investigated. This equates to a tendency for 
the trials to have an inadequate sample size resulting in 
less trial power than planned and increasing the risk of 
a type 2 error. The problem is demonstrated by the wide 
CIs around the estimates of mortality and effect size in 
table 1.
DIsCussIOn
We set out to explore whether or not there was a consistent 
pattern of underestimating control group mortality rates 
and using overambitious estimates of treatment effect in 
the design of sepsis trials, and we chose to examine this 
using effectiveness trials in severe sepsis and septic shock. 
Our results suggest that both of these ideas are correct.
Despite the overall improvements observed in 
mortality,1 the outlook for patients presenting with septic 
shock remains frustratingly uncertain. At best, an 18.8% 
control arm mortality rate (ARISE) still equates to 1 in 5 
of this patient cohort dying as a result of their illness.
The consistent overestimation of control arm event rate 
(or lower-than-anticipated actual control arm event rate) 
may have systematically led to undersized trials from the 
outset, that is, given the actual control arm mortality the 
trials would have been designed to include more patients. 
This has likely meant that there has been an increased 
risk of type 2 errors in many sepsis trials that could have 
potentially resulted in the disregarding of potentially 
useful treatments.
Figure 2 Anticipated and actual control arm mortality.  
Comparison for individual trials.
Figure 3 Anticipated and actual control arm 
mortality. Forest plot of the results of a random-effects meta-
analysis of the differences between the actual and anticipated 
control arm mortality (actual−anticipated).  The horizontal 
lines correspond to the 95% CI for each study , with the 
corresponding solid square proportional to the weight for that 
individual study in the meta-analysis.
Figure 4 Anticipated and actual effect size.
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An anticipated control arm event rate will remain, with 
traditional prospective trial design, an estimate. Power 
calculations should take into account the uncertainty 
in this input factor. The source data on which the esti-
mate will be based is always somewhat historical; investi-
gators will attempt to match the proposed population of 
study with that of a similarly matched group of previous 
patients. The ‘goal posts’ are, however, moving. We know 
patients are increasingly doing better and while we have 
not been able to ascertain the exact factors that are 
driving these improvements, they have the potential to 
influence our ability to evaluate novel treatments. Even 
the ARISE inception study,10 which collected data in 2006 
and 2007 (although for only 3 months) and generated 
anticipated control arm data for the early goal-directed 
therapy (EGDT) trial ARISE11 (enrolling in 2008 to 2014, 
n=1600), overestimated control arm mortality by 10% 
(28% vs 18.8%). There seem a number of plausible expla-
nations. There are potential influences from the quality 
and assimilation of source data where investigators are not 
anticipating improvements in secular trends in outcome 
or investigators are using data from previous control arms 
and historical cohorts that are not sufficiently current. 
Furthermore, investigators may, in some cases, be bound, 
consciously or subconsciously, by economic constraints 
that limit the uppermost sample size that can feasibly 
be funded. The total number of subjects required in 
statistically evaluating an intervention, in the context of 
contemporary severe sepsis and septic shock mortality, is 
formidable. If we consider the sample size required in a 
trial that aims to demonstrate a relative effect size of 10% 
(with fixed variables of alpha (0.05) and power (70%, 
80% or 90%)), then a fall in the population’s control arm 
mortality has a profound effect (figure 5). This relative 
effect size applied to a contemporary mortality figure 
in septic shock of 18.4% would require a trial of 13 400 
patients for the intervention arm’s mortality rate to fall 
to 16.56% (a 10% reduction relative to the control arm).
Effect size is a variable that is difficult to assess. We have 
used a post hoc analysis comparing the anticipated effect 
sizes that investigators estimated an intervention would 
have with the actual event rate in the study treatment 
arms. Investigators will use data from prior phase II (effi-
cacy) studies, often with subtly differing enrolment and 
exclusion criteria from the subsequent phase III (effec-
tiveness) trials. Phase II trials are conducted under as best 
circumstances as can be achieved and with a per protocol 
analysis of primary endpoint. Phase III effectiveness 
trials appropriately test interventions in the ‘real world’ 
and report using the intention to treat principle. This is a 
sterner/more complete test of an intervention. In addi-
tion, investigators estimate what they consider will be a 
clinically relevant effect.
The potential for patients enrolled in trials to fare 
better than those in a similar non-trial population is 
well recognised; teasing apart this ‘Hawthorne effect’ 
is difficult but may be important. The greater level of 
monitoring and general clinical surveillance may deliver 
subtle benefit. Trials of process of care may lose separa-
tion between groups, and thus erode measurement of 
treatment effect, as staff subtly alter their behaviour in 
response to what they see in the active or novel treatment 
arm. For trials aimed at delivering overall quality improve-
ment, often with ‘cluster’ randomisation,12 this is argu-
ably not so important. For studies aimed at determining 
the absolute impact of particular interventions, including 
an ethnographic element to describe changes in care and 
some metrics of the actual ‘dose’ of the element of care 
under test delivered may be wise.13
In failing to demonstrate relatively large effects, these 
trials have not excluded small beneficial effects; however, 
the confident demonstration of smaller effects requires 
much larger trials, which may not be fundable, or the 
effects sufficiently persuasive to change practice. Further 
complexities include treatment heterogeneity across 
disease severity, and heterogeneity of treatment risk, 
which do not necessarily align; a hypothetical smaller 
beneficial effect may not be matched with a smaller 
side-effect risk.14
Using conservative estimates of event rate and effect 
size seems an obvious solution, however, in trial terms 
critical illness is ‘noisy’ and inflating numbers to over-
come such noise in conventional trials is questionable. To 
quote David Sackett,15 “Reducing confidence intervals by 
increasing the size of an RCT should be your last resort”.
In the absence of consensus opinion on an appropriate 
effect size that would sway clinicians to employ a new entity 
in clinical practice, where should we draw the line? Have 
we reached a point where traditional randomised control 
trial methodology no longer provides us with informative 
and practice changing results? Should clinicians leading 
Figure 5 Power curve. The solid, dashed and dotted lines 
show the results of a standard sample size calculation to 
achieve 90%, 80% and 70% power, respectively. *The effect 
size is specified as a 10% reduction relative to the control 
arm mortality, so in absolute terms the effect size gets smaller 
as the control arm mortality gets smaller. For example, if 
the control arm mortality is 18.4%, then this equates to an 
absolute reduction in mortality of 1.84%. The red arrow 
shows that for a 5% alpha, 6700 patients are required for 
each arm to achieve 80% power.
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these trials, in collaboration with funders, shift towards 
composite endpoints (eg, long-term quality-of-life 
indices) instead of powering trials to a mortality benefit 
and would these metrics be sufficiently persuasive to 
change practice? Perhaps these difficulties in critical care 
research need to be addressed by exploring adaptive trial 
designs.16 17 Based on a series of a priori determined deci-
sion rules and rolling interim analyses, such trials evolve 
and redesign themselves as they proceed. The challenge 
here may be communicating the theoretical benefits of 
such designs to funders and review boards, and not least 
learning how to explain these to potential study subjects—
our patients—and their families.
Contributors JLCW: substantial contribution towards conception, design analysis 
and interpretation of the data. AJM: substantial contribution towards analysis and 
interpretation of data. ACG: substantial contribution in drafting work and revising 
it critically for important intellectual content. SJB: substantial contribution towards 
conception, design analysis and interpretation of the data. All authors approved 
of the final version. We agreed to be accountable for all aspects of the work and 
ensure accuracy and integrity.
Funding This study was supported by the National Institute for Health (NIHR) 
Comprehensive Biomedical Research Centre based at Imperial College Healthcare 
NHS Trust and Imperial College London. ACG is funded by a National Institute of 
Health Research (NIHR) Research Professorship award (RP-2015-06-018) 
Disclaimer The views expressed are those of the authors and not necessarily 
those of the NIHR, the NHS or the UK Department of Health.
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement The data in this paper are available from the published 
peer-reviewed literature.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
reFerenCes
 1. Kaukonen KM, Bailey M, Suzuki S, et al. Mortality related to severe 
sepsis and septic shock among critically ill patients in Australia and 
New Zealand, 2000–2012. JAMA 2014;311:1308–9.
 2. R Core Team. R: A language and environment for statistical 
computing. Vienna, Austria: R Foundation for Statistical Computing, 
2016.
 3. Kirkwood BR, Sterne JAC. Essential medical statistics. 2nd ed. New 
Jersey: Blackwell Publishing, 2003.
 4. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical 
Trials. 4 ed. New York, NY: Springer-Verlag New York, 2010.
 5. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy 
and pentastarch resuscitation in severe sepsis. N Engl J Med 
2008;358:125–39.
 6. Annane D, Timsit JF, Megarbane B, et al. Recombinant human 
activated protein C for adults with septic shock: a randomized 
controlled trial. Am J Respir Crit Care Med 2013;187:1091–7.
 7. Vincent JL, Ramesh MK, Ernest D, et al. A randomized, double-
blind, placebo-controlled, phase 2b study to evaluate the safety and 
efficacy of recombinant human soluble thrombomodulin, ART-123, 
in patients with sepsis and suspected disseminated intravascular 
coagulation. Crit Care Med 2013;41:2069–79.
 8. Yealy DM, Kellum JA, Huang DT, et al. A randomized trial of protocol-
based care for early septic shock. N Engl J Med 2014;370.
 9. Caironi P, Tognoni G, Masson S, et al. Albumin replacement 
in patients with severe sepsis or septic shock. N Engl J Med 
2014;370:1412–21.
 10. Peake SL, Bailey M, Bellomo R, et al. Australasian resuscitation of 
sepsis evaluation (ARISE): a multi-centre, prospective, inception 
cohort study. Resuscitation 2009;80:811–8.
 11. Peake SL, Delaney A, Bailey M, et al. Goal-directed resuscitation for 
patients with early septic shock. N Engl J Med 2014;371:1496–506.
 12. Pearse R. Enhanced peri-operative care for high-risk patients 
(EPOCH) trial: a stepped wedge cluster randomised trial of a quality 
improvement intervention for …. Lancet 2015.
 13. Walsh TS, Salisbury LG, Merriweather JL, et al. Increased hospital-
based physical rehabilitation and information provision after intensive 
care unit discharge: The RECOVER Randomized Clinical Trial. JAMA 
Intern Med 2015;175:901–10.
 14. Iwashyna TJ, Burke JF, Sussman JB, et al. Implications of 
heterogeneity of treatment effect for reporting and analysis of 
randomized trials in critical care. Am J Respir Crit Care Med 
2015;192:1045–51.
 15. Sackett DL. Why randomized controlled trials fail but needn't: 
2. Failure to employ physiological statistics, or the only formula 
a clinician-trialist is ever likely to need (or understand!). CMAJ 
2001;165:1226-37.
 16. Opal SM, Dellinger RP, Vincent JL, et al. The next generation 
of sepsis clinical trial designs: what is next after the demise 
of recombinant human activated protein C?*. Crit Care Med 
2014;42:1714–21.
 17. Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 
2016;375:65–74.
 18. Werdan K, Pilz G, Bujdoso O, et al. Score-based immunoglobulin 
G therapy of patients with sepsis: the SBITS study. Crit Care Med 
2007;35:2693–701.
 19. Russell JA, Walley KR, Singer J, et al. Vasopressin versus 
norepinephrine infusion in patients with septic shock. N Engl J Med 
2008;358:877–87.
 20. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for 
patients with septic shock. N Engl J Med 2008;358:111–24.
 21. Annane D, Cariou A, Maxime V, et al. Corticosteroid treatment and 
intensive insulin therapy for septic shock in adults: a randomized 
controlled trial. JAMA 2010;303:341–8.
 22. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin 
alfa (activated) in adults with septic shock. N Engl J Med 
2012;366:2055–64.
 23. Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 
130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 
2012;367:124–34.
 24. Opal SM, Laterre PF, Francois B, et al. Effect of eritoran, an 
antagonist of MD2-TLR4, on mortality in patients with severe sepsis: 
the ACCESS randomized trial. JAMA 2013;309:1154–62.
 25. Holst LB, Haase N, Wetterslev J, et al. Lower versus higher 
hemoglobin threshold for transfusion in septic shock. N Engl J Med 
2014;371:1381–91.
 26. Yealy DM, Kellum JA, Huang DT, et al. A randomized trial of protocol-
based care for early septic shock. N Engl J Med 2014;370:1683–93.
 27. Asfar P, Meziani F, Hamel JF, et al. High versus low blood-
pressure target in patients with septic shock. N Engl J Med 
2014;370:1583–93.
 28. Mouncey PR, Osborn TM, Power GS, et al. Trial of early, 
goal-directed resuscitation for septic shock. N Engl J Med 
2015;372:1301–11.
 o
n
 3 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020068 on 29 August 2018. Downloaded from 
